Archive for September 2019
Why It’s Crucial to Monitor FDA Guidances
By Mark Land, AAHP President It can take several years for manufacturers to implement new guidelines from the Food and Drug Administration (FDA)—and that means they could be at risk in the meantime. However, manufacturers can “get ahead of the game” by monitoring FDA’s guidance development agenda. FDA’s authority to readm more…
Read MoreAustralia to Release the First Draft Report on Homeopathy Effectiveness
By Mark Land, AAHP President Many believe the draft report arrived at a more encouraging conclusion regarding the effectiveness of homeopathy and may have been suppressed by the then conservative Australian government. After years of requests and inquiry, Australia’s National Health and Medical Research Council (NHMRC) has decided to readm more…
Read MoreAlert: FDA Drug Listing Records Subject to Inactivation
By Eric Foxman, AAHP Secretary Beginning September 14, 2019, and every January, FDA will begin to inactivate drug listings that are uncertified in the previous renewal period. Last month, the Food and Drug Administration (FDA) announced that it intends to inactivate drug listing records that are a) not certified readm more…
Read More